Thanks all for the comments on valuation - 

It's obvious to me that RVX market value is a reflection of the BOM trial and failure to reach endpoints. Current MV reflects the value of the NOL carryforwards and intellectual property steeply discounted for a spent R&D company. The company faces a ~ 5 year BOM2 trial for full redemption with an opportunity to go to market with a succesful interim analysis - maybe 2-3 years out at a cost of $160mm. About the current mv of the company - not very attractive at this stage of the game.

In DMs words - 'we have a drug that works and has demonstrated safety in human clinical trials'.

The recent scientific publications in prestigious journals on apabetalone's effectiveness as a therapy for preventing cycotine storm and damage to the heart, lungs and kidneys are a testimony to the efficacy of the drug - in human trials it has been proven safe. The upcoming Sars-Covid 19 Phase II will validate those assumptions. APB may also prove effective in variants of the virus.

New deadly viruses and variants require new therapeutics and MOA's and have created an enourmous opportunity for RVX in repurposing this dual mechanism.

A succesful Phase II SARS-Covid 19 trial will increase the MV of this stock. 

A succesful PHASE III SARS-Covid 19 trial will icrease the price exponentially

Meticulate trial design and implementation is extremely important. 

The stage is set.

jmo

Chicagoest